海创药业股份有限公司 简式权益变动报告书 上市公司名称：海创药业股份有限公司 股票上市地点：上海证券交易所 股票简称：海创药业 股票代码：688302 信息披露义务人：成都盈创动力创业投资有限公司 注册地址：中国（四川）自由贸易试验区成都高新区天府大道北段 1480 号高新孵化园 12 号楼 A 座 103 号 通讯地址：中国（四川）自由贸易试验区成都高新区天府大道北段 1480 号高新孵化园 12 号楼 A 座 103 号 权益变动性质： 股份减少（持股比例下降至 5%） 签署日期：2025 年 7 月 31 日 信息披露义务人声明 一、本报告书系信息披露义务人依据《中华人民共和国公司法》《中 华人民共和国证券法》《上市公司收购管理办法》《公开发行证券的公 司信息披露内容与格式准则第 15 号——权益变动报告书》及其他相 关法律、法规和部门规章的有关规定编写。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行 亦不违反信息披露义务人公司章程或内部规则中的任何条款，或与之 相冲突。 三、依据《中华人民共和国证券法》《上市公司收购管理办法》和《公 开发行证券的公司信息披露内容与格式准则第 15 号— ...

Group 1 - The Chinese innovative drug industry is transitioning from "follow-up innovation" to "global leadership," with a record number of innovative drugs approved in the first half of the year [1][2] - In the first half of 2023, 43 innovative drugs were approved in China, representing a 59% year-on-year increase, compared to only 48 approvals for the entire year of 2024 [2][3] - China's innovative drug R&D pipeline accounts for about one-fourth of the global total, with approximately 3,000 clinical trials conducted annually, placing China at the forefront of global innovative drug development [2][3] Group 2 - Companies like Fosun Pharma and Hengrui Medicine have successfully launched multiple innovative drugs, with Hengrui having 23 first-class innovative drugs and 4 second-class innovative drugs approved domestically [3][4] - The commercialization of innovative drugs is leading to a recovery in performance for domestic pharmaceutical companies, with companies like Luoxin Pharma and MicuRx reporting significant profit increases [3][4] - The trend of Chinese pharmaceutical companies expanding internationally is accelerating, with a shift from license-in to explosive growth in license-out transactions, contributing nearly 50% of the total transaction value globally [4][5] Group 3 - Notable license-out deals include a partnership between 3SBio and Pfizer, with an upfront payment of $1.25 billion and a potential total deal value of $6.05 billion, setting a record for Chinese innovative drugs [5][6] - The rapid growth of license-out transactions is providing substantial cash flow for domestic innovative drug companies, supporting their core pipelines overseas and creating more collaboration opportunities with multinational pharmaceutical companies [6]

Core Insights - The Chinese pharmaceutical industry is experiencing a resurgence after three years of stagnation, driven by high-value licensing deals from multinational pharmaceutical companies [1][2] - There is a significant interest from overseas investors in Chinese biopharmaceutical companies, with a notable increase in licensing agreements and IPO activities [2][8] - The trend of "licensing out" Chinese drug candidates to foreign companies is becoming more common, providing Chinese firms with milestone payments and a share of sales revenue [4][6] Group 1: Market Dynamics - As of mid-July, approximately 288 companies are waiting for IPOs in Hong Kong, many of which are biopharmaceutical firms seeking to list under the 18A rule [1][8] - The Hong Kong medical sector has seen a 54% increase this year, significantly outperforming the MSCI China Index, which rose by 17% [8] - The average price-to-earnings (PE) ratio for the sector is around 30 times, placing it in the 15th percentile of its valuation range over the past five years [8] Group 2: Investment Trends - U.S. investment banks are playing a crucial role in facilitating these licensing deals and IPOs, with cornerstone investors contributing 42% of IPO financing this year, two-thirds of which comes from overseas [1][12] - The trend of U.S. pharmaceutical companies seeking to lower costs through partnerships with Chinese firms is expected to continue, especially in light of U.S. drug pricing policies [2][6] Group 3: Licensing Agreements - The number of licensing transactions from China has increased significantly, with 35 deals in 2023 and projected to reach 43 in 2024, alongside a total upfront payment of $2.957 billion in 2023 [3][6] - Notable licensing agreements include Akeso's ivonescimab, which was licensed to Summit Therapeutics for a total value of $5 billion, marking one of the largest overseas licensing deals in Chinese biopharmaceutical history [7][6] Group 4: Future Outlook - Chinese biopharmaceutical companies are increasingly able to produce globally recognized clinical data, particularly in competitive fields like oncology and immunology [2][6] - The shift from merely selling drug pipelines to achieving global commercialization is essential for the future growth of Chinese pharmaceutical companies [13][15] - There is a need for Chinese firms to enhance their innovation capabilities and international execution to compete effectively on a global scale [14][15]

Group 1: Pharmaceutical Industry - The State Medical Insurance Administration and the National Health Commission introduced measures to support the high-quality development of innovative drugs, including 16 specific actions to enhance the entire chain of drug development, approval, and payment [1][2] - The approval process for innovative drugs has been accelerated, with clinical trial applications expected to be reviewed within 30 working days, which is anticipated to boost market confidence in the innovative drug sector [2] - The first version of the Class B drug directory is set to be released within the year, focusing on highly innovative and clinically valuable drugs, which will support the role of commercial health insurance in the multi-tiered medical security system [2] Group 2: AI Applications and Computing Power - The GB300 has successfully entered mass production, indicating a positive trend in the Nvidia supply chain, with increased demand for high-end PCBs, optical modules, and server ODMs [3] - Domestic AI models are rapidly evolving, with significant growth in daily token consumption, indicating a substantial demand for computing power in AI applications [3] - The release of Grok 4 by Musk is expected to further drive capital expenditure among major companies, with market anticipation for the potential release of GPT-5 [4] Group 3: Robotaxi Market - The Robotaxi market in China is projected to reach $44.5 billion by 2035, with a compound annual growth rate (CAGR) of 96% from 2025 to 2035, indicating a significant growth opportunity in the smart vehicle sector [7] - The current penetration rate of Robotaxi in China is less than 1%, with major companies operating fewer than 3,000 vehicles, suggesting a substantial opportunity for expansion [7] Group 4: Anti-Competition Regulations - The revised Anti-Unfair Competition Law aims to address "involution" in competition, prohibiting the sale of products below cash cost, which is expected to improve pricing dynamics in the solar and lithium battery sectors [9][10] - The focus on eliminating low-price competition is anticipated to lead to a recovery in profitability across various industries, including solar and lithium batteries [9][10] Group 5: Capital Market Developments - The introduction of the "Science and Technology Innovation Board Growth Layer" provides a financing channel for technology companies that are not yet profitable, broadening the scope for investment in innovative sectors [16][17] - The first batch of companies entering the growth layer includes 32 firms across various industries, with a significant concentration in pharmaceuticals and electronics [20] - The total fundraising scale in the A-share market has surged, with a year-on-year increase of 608.81%, indicating a strong trend towards capital raising in key sectors [23]

Group 1 - The financing balance of the Sci-Tech Innovation Board increased by 115 million yuan compared to the previous day, marking an increase for eight consecutive trading days [1] - As of July 23, the total margin financing balance on the Sci-Tech Innovation Board reached 165.993 billion yuan, with a financing balance of 165.389 billion yuan [1] - There are 435 stocks on the Sci-Tech Innovation Board with a financing balance exceeding 100 million yuan, and 17 stocks have a financing balance over 1 billion yuan [1] Group 2 - The stock with the highest net financing purchase is Shangwei New Materials, with a latest financing balance of 26.818 million yuan, increasing by 94.9546 million yuan, and the stock rose by 19.73% on that day [2] - Other stocks with significant net purchases include Electric Wind Power and Haichuang Pharmaceutical, with net purchases of 66.8525 million yuan and 54.0988 million yuan, respectively [2] - The average increase for stocks with net purchases exceeding 10 million yuan was 0.84%, with Electric Wind Power and Shangwei New Materials leading the gains [2] Group 3 - The industry sectors favored by financing customers include pharmaceuticals, electronics, and machinery, with 13, 12, and 11 stocks respectively [2] - The average ratio of financing balance to circulating market value for stocks with significant net purchases is 4.49%, with Xinyu Ren having the highest ratio at 9.53% [2] - Other stocks with high financing balance ratios include Huahai Chengke, Yangguang Nuohuo, and Yinuosi, with ratios of 8.49%, 8.31%, and 8.00% respectively [2]

Summary of Key Points Core Viewpoint - On July 18, a total of 16 stocks on the Sci-Tech Innovation Board (STAR Market) experienced block trading, with a cumulative transaction amount of 171 million yuan, indicating active trading activity in this sector [1]. Group 1: Trading Activity - A total of 31 block trades were recorded, with a cumulative trading volume of 4.8367 million shares [1]. - The stock with the highest transaction amount was Haitan Ruisheng, which had 9 block trades totaling 38.30 million shares and a transaction amount of 38.30 million yuan [1]. - Other notable stocks in terms of transaction amounts included Guangyun Technology and Fuchuang Precision, with transaction amounts of 24.9162 million yuan and 20.9360 million yuan, respectively [1]. Group 2: Price and Discount Analysis - The stocks that experienced the highest discount rates relative to their closing prices included Qingyun Technology, Weixin Bio, and Guangyun Technology, with discount rates of 19.48%, 17.25%, and 14.95%, respectively [1]. - The average increase for the stocks involved in block trading was 2.55%, with the top gainers being Dema Technology, Qingyun Technology, and Huasheng Lithium, which saw increases of 14.74%, 7.90%, and 7.22% respectively [1]. Group 3: Institutional Participation - Among the block trades, 12 transactions involved institutional buyers or sellers, with the highest buying amounts for Haitan Ruisheng, Guangyun Technology, and Qingyun Technology, at 27.70 million yuan, 11.2276 million yuan, and 7.579 million yuan, respectively [2]. - In terms of net capital flow, six stocks saw net inflows, with Dema Technology, Huasheng Lithium, and Qingyun Technology leading with net inflows of 51.1035 million yuan, 33.284 million yuan, and 32.1246 million yuan, respectively [2].

不到一个月，科创板改革"1+6"政策迎来新进展。7月13日，上海证券交易所发布了《上海证券交易所科创板上市公司自律监管指引第5号——科创 成长层》（简称《科创成长层指引》）等一系列重要通知，并自发布之日起施行。这意味着，市场期待已久的科创成长层等系列举措正式落地。 根据配套业务规则，科创板存量32家未盈利企业将自《科创成长层指引》发布实施之日起进入科创成长层，新注册的未盈利企业将自上市之日起 进入；借鉴境外市场的经验，在科创板试点引入IPO预先审阅机制；在科创板试点引入资深专业机构投资者制度，从适用科创板第五套上市标准的 申报企业开展试点，鼓励发行人自主认定并充分披露资深专业机构投资者入股情况。 科创成长层调出条件实施"新老划断" 备受关注的《科创成长层指引》发布实施后，上交所表示将重点抓好坚守科创成长层定位、科创成长层调出条件实施"新老划断"、强化风险导向 信息披露、加强投资者适当性管理4个方面工作，推动改革尽快落地见效。 对于"准入门槛"，上交所表示，这次改革没有针对未盈利企业纳入科创成长层设置额外的上市门槛，存量32家未盈利企业将自指引发布实施之日 起进入科创成长层，新注册的未盈利企业将自上市之日起进入 ...

Core Viewpoint - The establishment of the "Science and Technology Innovation Growth Layer" in the STAR Market aims to support high-quality, unprofitable technology companies, enhancing the inclusiveness and adaptability of the capital market [2][4]. Group 1: Policy and Regulatory Changes - The China Securities Regulatory Commission (CSRC) emphasizes the need for a more inclusive and adaptable regulatory framework, focusing on deepening reforms in the STAR Market and the Growth Enterprise Market [2]. - The CSRC issued the "Opinions on Setting Up a Science and Technology Innovation Growth Layer in the STAR Market," which outlines the basic requirements for this new layer [4]. - The Shanghai Stock Exchange (SSE) has released supporting business rules to facilitate the implementation of the Growth Layer [2][4]. Group 2: Entry and Exit Criteria - The Growth Layer is designed to support unprofitable technology companies without imposing additional listing thresholds for them [4]. - A total of 32 existing unprofitable companies will automatically transition to the Growth Layer, while newly registered unprofitable companies will enter upon listing [4]. - The exit criteria for existing companies remain unchanged, requiring them to achieve profitability after listing, while new unprofitable companies will face stricter exit conditions [5]. Group 3: Investor Management and Disclosure - The reform does not introduce new trading thresholds for individual investors, maintaining the existing requirement of 500,000 yuan in assets and two years of investment experience [5]. - Investors must sign a risk disclosure agreement before investing in newly registered unprofitable technology companies in the Growth Layer [5]. - Companies in the Growth Layer are required to disclose risks related to unprofitability and technology development in their annual reports and interim announcements [5]. Group 4: Pre-Review Mechanism - The pre-review mechanism is a significant innovation aimed at protecting sensitive business information while allowing companies to seek guidance before formal IPO applications [8][9]. - Companies must justify the necessity of a pre-review, and the SSE will ensure compliance with the established rules during this process [8][9]. Group 5: Professional Investor Recognition - The SSE has introduced guidelines for recognizing "senior professional institutional investors," which will help identify high-quality technology companies [10][11]. - The criteria for recognition include governance structure, asset management scale, and investment experience in technology companies [11]. - The involvement of recognized professional investors is expected to enhance the credibility of companies and assist in identifying those with genuine growth potential [13].

Group 1 - The Shanghai Stock Exchange has released the "Self-Regulatory Supervision Guidelines for Companies Listed on the Sci-Tech Innovation Board No. 5 - Sci-Tech Growth Tier" [1] - The reform does not impose additional listing thresholds for unprofitable companies entering the Sci-Tech Growth Tier, allowing 32 existing unprofitable companies to enter immediately upon the guideline's implementation [1] - Newly registered unprofitable companies will enter the Sci-Tech Growth Tier from the date of their listing [1] Group 2 - Investors participating in the subscription and trading of newly registered stocks in the Sci-Tech Growth Tier must sign a "Risk Disclosure Statement for the Sci-Tech Growth Tier" [2] - The 32 existing companies that have not yet removed the "U" designation include: Zejing Pharmaceutical, Junshi Biosciences, Frontier Biotech, Qingyun Technology, Hehui Optoelectronics, Jingjin Electric, BeiGene, Dize Pharmaceutical, Maiwei Biotech, Aojie Technology, Yuhong Pharmaceutical, Shouyao Holdings, Haichuang Pharmaceutical, CloudWalk Technology, Yifang Biotech, Obsidian Optics, Mengke Pharmaceutical, Nuo Cheng Jianhua, Xinke Mobile, Xinghuan Technology, Yutai Micro, Yuntian Lifa, Tianzhihang, Qi Anxin, Hanwujin, Yihua Tong, Aifute, Huizhiwei, Xinlian Integrated, Zhixiang Jintai, Shengke Communication, and Zhongjuxin [2]

Core Viewpoint - Haichuang Pharmaceutical Co., Ltd. has launched its self-developed innovative anti-cancer drug, Dihydro-Enzalutamide soft capsule, marking a significant milestone in its development journey [2][3] Group 1: Product Launch and Clinical Significance - Dihydro-Enzalutamide soft capsule is recognized as a new type of androgen receptor antagonist (ARi) and has shown significant clinical value, particularly in treating metastatic castration-resistant prostate cancer (mCRPC) [2] - Clinical studies indicate that Dihydro-Enzalutamide significantly improves disease progression and survival rates while demonstrating excellent safety profiles, with no adverse events such as falls or seizures reported [2] - Experts suggest that Dihydro-Enzalutamide has the potential to be moved forward in treatment protocols for metastatic hormone-sensitive prostate cancer (mHSPC) [2][3] Group 2: Company Development and Future Plans - The inauguration of Haichuang Pharmaceutical's headquarters and the rapid nationwide supply of Dihydro-Enzalutamide signify a critical leap from research innovation to industrial empowerment [3] - The company focuses on developing innovative drugs for cancer and metabolic diseases and plans to accelerate the global rollout of multiple anti-cancer and metabolic disease drugs [3] - Haichuang Pharmaceutical's chairman emphasized the importance of patient-centered research and the collective effort of employees and partners in achieving this milestone [3]